NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 157)
Posted On: 12/13/2022 3:53:23 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in ‘Stock2Me’ Podcast
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Stock2Me Podcast, an IBN solution to provide specialized content distribution via widespread syndication channels. BiondVax’s CEO Amir Reichman joined the latest episode to introduce the company and discuss its recent development efforts focused on innovative nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments and with large and growing markets. “[While attempting to develop the universal influenza vaccine], BiondVax built a state-of-the-art facility in Jerusalem. It’s a manufacturing facility that includes almost all of the steps of biological production… What we didn’t have at the time that I joined was the IP… We ended up contracting with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen,” Reichman said during the interview with IBN’s Stuart Smith. “With these two institutes, we entered three contracts. One is an exclusive license for development and commercialization of a self-inhaled COVID-19 therapeutic. The second was an accompanying research collaboration agreement… The third contract was a five-year strategic research collaboration contract with these two institutes for the discovery and development of nanobodies for the treatment of additional diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Stock2Me Podcast, an IBN solution to provide specialized content distribution via widespread syndication channels. BiondVax’s CEO Amir Reichman joined the latest episode to introduce the company and discuss its recent development efforts focused on innovative nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments and with large and growing markets. “[While attempting to develop the universal influenza vaccine], BiondVax built a state-of-the-art facility in Jerusalem. It’s a manufacturing facility that includes almost all of the steps of biological production… What we didn’t have at the time that I joined was the IP… We ended up contracting with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen,” Reichman said during the interview with IBN’s Stuart Smith. “With these two institutes, we entered three contracts. One is an exclusive license for development and commercialization of a self-inhaled COVID-19 therapeutic. The second was an accompanying research collaboration agreement… The third contract was a five-year strategic research collaboration contract with these two institutes for the discovery and development of nanobodies for the treatment of additional diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)